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This doctoral dissertation summarizes the effects of statins and inflammation on TGF-β1 signaling both in 
vivo and in vitro, especially the role of endoglin in the endothelial cells. 
Transforming growth factor-β (TGF-β) is a multifunctional factor that regulates various cell specific functions 
in atherogenesis. Endoglin (TGF-βRIII, CD105) is known as accessory TGF β receptor, and it is able to 
modulate activity of TGF-β1 and TGF-β receptors. Previous studies demonstrated relation between endoglin 
and eNOS expression in blood vessels suggesting crucial role of endoglin in endothelial cell functions. 
Our in vivo experimental studies, were focused on the expressions of TGF-β family members, on endoglin 
expression in aorta and its blood serum levels. We wanted to evaluate, whether these proteins are affected 
by cholesterol levels or atorvastatin treatment in different types of diet in mice. Immunohistochemical 
analysis showed the expression of endoglin in intact endothelium and in endothelium covering 
atherosclerotic lesions. Moreover, co localization of endoglin, Smad2, pSmad2/3 and eNOS in aortic 
endothelium was described. Cholesterol feeding resulted in an increased cholesterol and soluble endoglin 
levels in blood serum, with concurrent decrease of its expression in aorta. Atorvastatin treatment in mice on 
chow diet resulted in a significant increase of cholesterol, whereas endoglin levels in blood serum remained 
unchanged. Moreover, Western blot analysis revealed that atorvastatin treatment significantly increased the 
expression of endoglin and other proteins of TGF-β signaling in aorta beyond its lipid lowering effects. The 
administration of atorvastatin in cholesterol fed mice resulted in a significant decrease of cholesterol and 
endoglin levels in blood serum, with concurrent increase of endoglin expression in aorta. These data show 
that endoglin blood serum levels and its expression in aorta are affected by both atorvastatin treatment and 
cholesterol levels in ApoE/LDLR double knockout mice. Moreover, changes in blood serum levels are 
conversely related to endoglin expression in aorta. Thus, we propose that endoglin might be interesting 
blood marker, which could reflect atherosclerotic process in the vessel wall and efficiency of statin treatment. 
Moreover, activation of endoglin/ALK 5/Smad2/3 signaling might represent protective mechanism in aortic 
endothelium. 
In our in vitro study, we focused on endoglin and eNOS expression during inflammation and after 
atorvastatin treatment in HUVEC cells. We also hypothesized whether statin induced eNOS expression 
depends on endoglin. Atorvastatin treatment significantly increased endoglin and eNOS expression in 
HUVECs. TNFα treatment for 16h significantly reduced endoglin expression, together with significant 
increase of soluble endoglin in medium. Atorvastatin pretreatment, before TNFα exposure, significantly 
prevented decrease of endoglin and eNOS expression mediated by TNFα. These results showed that 
inflammation reduces expression of endoglin and eNOS in HUVECs, which could be prevented by 
atorvastatin treatment. Moreover, endoglin siRNA experiment showed, that atorvastatin induced eNOS 
expression seems to be dependent on proper endoglin expression. 
Endoglin and eNOS play important role in various cardiovascular pathologies including atherosclerosis, 
hypertension, diabetes, preeclampsia and hereditary hemorrhagic telangiectasia. For these reasons, we 
propose that statin effects on endoglin signaling and its regulation of eNOS expression may contribute to the 
positive effects on atherosclerosis and other diseases where lower levels of endoglin and eNOS were 
described including hereditary hemorrhagic telangiectasia. However, this hypotheses must be evaluated in 
clinical studies. 
